2. Autophagy
  3. Autophagy
  4. PFK-015

PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC).

For research use only. We do not sell to patients.

CAS No. : 4382-63-2

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

PFK-015 Related Antibodies

Top Publications Citing Use of Products
Bio/Physico-chemical Assay
WB
Cell Proliferation/Viability Assay
Cell Migration/Invasion Assay

    PFK-015 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Dec 18;43(1):113557.  [Abstract]

    PFKFB3 inhibitor PFK-015 dose response of DIPG IV, SF8628, and DIPG 13p cell lines.

    PFK-015 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2023 Dec 18;43(1):113557.  [Abstract]

    Cell proliferation (relative fluorescence units, RFU) for DIPG IV and SF8628 cells treated with PFK-015 (0.9, 1.2 μM) compared to vehicle control.

    PFK-015 purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2024 Jan 1:579:112083.  [Abstract]

    11Z and EESCs cells were co-cultured with PFK-015 for 24 h and their medium supernatants were collected to determine glucose and lactate concentrations (IC50: 11Z, 4.071 μmol/L; EESCs, 3.116 μmol/L).

    PFK-015 purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2024 Jan 1:579:112083.  [Abstract]

    PFK-015 (0-30 μM) inhibited 11Z and EESCs cell viability in a dose-dependent manner.

    PFK-015 purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2024 Jan 1:579:112083.  [Abstract]

    PFK-015 (24 h) suppressed the protein intracellular expression of PFKFB3.

    PFK-015 purchased from MedChemExpress. Usage Cited in: Mol Cell Endocrinol. 2024 Jan 1:579:112083.  [Abstract]

    11Z and EESCs cells were plated in 6-well plates, and PFK-015 was added to the experimental group and cultured for 10–14 days to observe the colony formation.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC)[1][2].

    IC50 & Target

    IC50: 110 nM (recombinant PFKFB3); IC50: 20 nM (PFKFB3 activity in cancer cells)[2]
    In Vitro

    PFK-015 inhibits tumor growth in a dose-dependent manner in esophageal cancer cell line in vitro[1].
    PFK-015 (0-5 μM) increases HIF-1α mediated PD-L1 transcriptional activity[1].
    ? ? PFK-015 induces the expression of tumor PD-L1 via the phos-PFKFB3/HIF-1a axis[1].
    ? PFK-015 potently inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM[2].
    ? PFK-015 inhibits cancer cell proliferation in a panel of 17 cancer cell lines and suppresses glucose uptake in cancer cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    PFK-015 Related Antibodies
    In Vivo

    PFK-015 impeds ESCC tumor growth in immunodeficient in vivo models[1].
    ? ? PFK-015 (0-12.5 μM, 48 h) induces tumor PD-L1 expression[1].
    ? ? PFK-015 (0-12.5 μM, 48 h) can cause a downregulation of immune activity against tumor cells mediated by CD8 + T cells[1].
    ? ? PFK-015 enhances the efficacy of ESCC by enhancing CD8 + T-cell activity combining PD-1 mAb in immunocompetent mouse models such as C57BL/6 and hu-PBMC-NOG[1].
    ? PFK-015 (iv, 5 mg/kg) has a satisfactory half-life, exposure, tissue distribution and reasonable clearance[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    260.29

    Formula

    C17H12N2O
    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    O=C(C1=CC=NC=C1)/C=C/C2=NC3=CC=CC=C3C=C2
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 25.2 mg/mL (96.82 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.8419 mL 19.2093 mL 38.4187 mL
    5 mM 0.7684 mL 3.8419 mL 7.6837 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2 mg/mL (7.68 mM); Clear solution

      This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2 mg/mL (7.68 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.8419 mL 19.2093 mL 38.4187 mL 96.0467 mL
    5 mM 0.7684 mL 3.8419 mL 7.6837 mL 19.2093 mL
    10 mM 0.3842 mL 1.9209 mL 3.8419 mL 9.6047 mL
    15 mM 0.2561 mL 1.2806 mL 2.5612 mL 6.4031 mL
    20 mM 0.1921 mL 0.9605 mL 1.9209 mL 4.8023 mL
    25 mM 0.1537 mL 0.7684 mL 1.5367 mL 3.8419 mL
    30 mM 0.1281 mL 0.6403 mL 1.2806 mL 3.2016 mL
    40 mM 0.0960 mL 0.4802 mL 0.9605 mL 2.4012 mL
    50 mM 0.0768 mL 0.3842 mL 0.7684 mL 1.9209 mL
    60 mM 0.0640 mL 0.3202 mL 0.6403 mL 1.6008 mL
    80 mM 0.0480 mL 0.2401 mL 0.4802 mL 1.2006 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    PFK-015 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    PFK-0154382-63-2PFK015PFK 015AutophagyPFKFB33POcancerslung cancerstomach cancercolon canceresophageal squamous cell carcinoma (ESCC)Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    PFK-015
    Cat. No.:
    HY-12204
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.